Radiotheranostics coupled between an At-211-Labeled RGD peptide and the corresponding radioiodine-labeled RGD peptide

Alpha particle-emitting radionuclides have gained considerable attention for radionuclide therapy. Astatine-211 ( 211 At) is a promising alpha particle-emitting radionuclide. 211 At is a halogen that has similar chemical properties to iodine and exhibits a half-life of 7.2 h. However, direct labeling of proteins or peptides into the tyrosine residue with 211 At was shown to be impractical. Herein, we demonstrate a novel 211 At-labeling method using the RGD peptide as a model peptide. An 211 At-labeled RGD peptide, [ 211 At]c[RGDf(4-At)K], was prepared from a precursor with a tributylstannyl group on the phenylalanine residue in c(RGDfK) with a radiochemical yield of 63% and a radiochemical purity of >96%, and its potential for targeted radionuclide therapy was evaluated. Based on the results of biodistribution experiments, [ 125 I]c[RGDf(4-I)K] and [ 211 At]c[RGDf(4-At)K] showed high accumulation in the tumor and similar biodistribution. This study provides useful information for radiotheranostics between an 211 At-labeled peptide and the corresponding radioiodine-labeled peptide. © 2019 American Chemical Society.

内容記述

内容記述タイプ

Other

内容記述

This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

権利

権利情報

著者版フラグ

出版タイプ

VoR

出版タイプResource

http://purl.org/coar/version/c_970fb48d4fbd8a85

Versions

Ver.1

2023-07-27 10:17:53.401723

Show All versions

Cite as

エクスポート

OAI-PMH

JPCOAR 2.0
JPCOAR 1.0
DublinCore
DDI

Other Formats

JSON
BIBTEX

インデックスリンク

インデックスツリー

アイテム